FDA extends review period for Applied Therapeutics’ govorestat by three months
Yesterday Applied Therapeutics announced that the FDA is extending the review period for its investigational aldose reductase inhibitor govorestat for the treatment of classic galactosemia. The biotech now expects a verdict by Nov. 28, 2024.